Recent Updates
Recently added Catalysts
BBIO

BridgeBio Pharma to Participate in June Investor Events

Key Takeaway: PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in
Price reaction · baseline $7.22 (2022-06-03 close) · 1 other BBIO headline(s) in the window, move may be shared
day 0 close · peak
-2.9%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis

Full Press Release Details

PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:
Jefferies Healthcare Conference, New York, NY: Thursday, June 9th at 4:00 pm ET
Goldman Sachs Global Healthcare Conference, Ranchos Palos Verdes, CA: Wednesday, June 15th at 5:00 pm ET
To access the live webcast of BridgeBio’s presentations, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
Last updated: Jun 6, 2022